FDG PET/CT评估转移性乳腺癌患者股骨病理性骨折风险
回顾性病例对照研究纳入27例转移性乳腺癌伴股骨近端病理性骨折患者和55例无骨折对照,评估FDG PET/CT定量指标对骨折风险的判别能力。4项FDG摄取定量指标在两组间均有统计学差异(P<0.001),总病灶糖酵解值81可区分骨折与无骨折患者,准确度0.83、敏感度0.85、特异度0.80。
要点
- 27例骨折患者与55例无骨折对照的4项FDG定量指标均有统计学差异(P<0.001)。
- 总病灶糖酵解值81区分骨折与无骨折的准确度0.83、敏感度0.85、特异度0.80。
- FDG摄取定量指标可能有助于识别股骨近端病理性骨折高风险患者。
核心结论
- FDG摄取定量指标可能有助于识别转移性乳腺癌患者中股骨近端后续病理性骨折的高风险者。
研究设计与样本
- 符合《健康保险可携带性与责任法案》的回顾性病例对照研究,经机构审查委员会豁免开展。
- 病例为2008年1月至2014年12月接受FDG PET/CT且PET/CT后3个月内发生股骨近端病理性骨折的转移性乳腺癌患者。
- 对照为2013年接受FDG PET/CT、按逆时间顺序连续筛选、PET/CT显示股骨近端转移但后续无病理性骨折的转移性乳腺癌患者。
- 预设目标是对照数量为病例的两倍;最终纳入27例病理骨折病例和55例无病理骨折对照。
主要发现
- 27例病理骨折病例与55例无病理骨折对照中,4项FDG摄取定量指标在两组间均有统计学差异(P<0.001)。
- 总病灶糖酵解值为81时可区分骨折与无骨折患者,准确度0.83、敏感度0.85、特异度0.80。
关键数值与推荐
- 分析靶病灶为股骨近端(股骨头至小转子下方5 cm),测量SUVmax、SUVmean、代谢性肿瘤体积和总病灶糖酵解值。
- 采用Wilcoxon秩和检验比较病例与对照的连续变量。
- 采用非参数受试者工作特征分析评估FDG定量指标区分病例与对照的能力。
- 总病灶糖酵解值81区分骨折与无骨折患者的准确度0.83、敏感度0.85、特异度0.80。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Assessment of pathological fracture risk is critical to optimize the use of prophylactic orthopedic fixation to prevent pathological fractures. Better prediction of pathological fracture risk is needed. We evaluated if quantitative measures of FDG avidity can assess femoral pathological fracture risk in patients with metastatic breast cancer (MBC). PATIENTS AND METHODS: A Health Insurance Portability and Accountability Act-compliant retrospective case-control study was performed under institutional review board waiver. Patients with MBC who received an FDG PET/CT from January 2008 to December 2014 and had pathological fracture of the proximal femur within 3 months of PET/CT were selected as cases. Patients with MBC who had an FDG PET/CT in 2013 were sequentially screened in reverse chronological order to identify patients with proximal femoral metastases on PET/CT but no subsequent pathological fracture to serve as a control group. The prespecified goal was to have twice the number of controls as cases. Target lesions in the proximal femur, from femoral head to 5 cm below the lesser trochanter, were analyzed on FDG PET/CT for SUVmax, SUVmean, metabolic tumor volume, and total lesion glycolysis. Wilcoxon rank sum test was used to compare continuous variables in cases and controls. A nonparametric receiver operating characteristic analysis was performed to assess the ability of quantitative FDG measurements to differentiate between cases and controls. RESULTS: In 27 cases with pathological fracture and 55 controls without pathological fracture, all 4 quantitative measures of FDG avidity were statistically different between cases and controls (P < 0.001). A total lesion glycolysis of 81 could differentiate between fracture and nonfracture patients with accuracy, sensitivity, and specificity of 0.83, 0.85, and 0.80, respectively. CONCLUSIONS: Quantitative measures of FDG avidity may help identify breast cancer patients at high risk of subsequent pathological fracture of the proximal femur.
引用
- Ulaner GA, Zindman AM, Zheng J, et al. FDG PET/CT Assesses the Risk of Femoral Pathological Fractures in Patients With Metastatic Breast Cancer. Clin Nucl Med. 2017. PMID: 28166159. doi:10.1097/RLU.0000000000001580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。